港股異動丨友邦保險(1299.HK)跌逾4% 廣東疫情致香港與內地通關再增添變數
格隆匯5月31日丨友邦保險(1299.HK)跌逾4%,再度跌破100港元大關,至99.05港元,總市值11982億港元。廣東省衞健委通報,5月30日0-24時,新增本土確診病例20例(其中16例為無症狀感染者轉確診),廣州報吿18例(其中14例為無症狀感染者轉確診),佛山報吿2例(均為無症狀感染者轉確診);新增本土無症狀感染者3例。友邦此前表示,自去年2月起內地與香港之間通關受限,導致內地訪客的新業務銷售幾乎陷入停頓。據友邦保險披露的數據顯示,去年香港市場的新業務價值同比大幅減少66%,年化新保費亦下跌逾50%至11.38億元。近期的廣東疫情讓香港社會期待的通關再增添變數。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.